Plus: Aprinoia, SPAC terminate merger agreement and Exelixis’ cabozantinib shows PFS benefit in NETs and updates on the IRA, RSV and more 

Plus: Peterson joins Exelixis, Eckhardt expands role at Bayer and updates from Alpine, Neuron23, Ajax

Plus: Andreessen Horowitz co-leads $200M round for AI company Genesis, Leqembi closes in on Japan approval and more

Plus: Incyte stopping Jakafi myelofibrosis combo study and updates from Exelixis, Sangamo, BMS, Veru

Selective VEGFR inhibitor improved survival in multi-regional study; regulatory submission started in U.S., other markets to follow

ATP-backed biotech gets $45M up front for pair of molecules derived from STAR platform, extending runway with first-in-human trial due this year

Budget-priced $247M acquisition of epigenetics pioneer with slow-selling drug could deliver more value to Epizyme’s shareholders via CVR

Plus a positive opinion for Evusheld and label extensions for five medicines

Plus Ascendis meets in hypoparathyroidism and updates from BridgeBio, AZ, Sanofi, Pfizer and more